Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

McGill University

$105,000.00

A new role for EHMT1 in repressing NF-kB and TGFb signaling in Kleefstra Syndrome

EF 2023-24

Résumé
Kleefstra syndrome (KS) is a neurodevelopmental disorder characterized by intellectual disability, low muscle tone, impaired immune responses, and craniofacial deformities. Genetic work has revealed the cause of KS to be the loss of one copy of the EHMT1 gene, though how decreases in EHMT1 expression cause disease is unclear. Recently, our lab has shown that EHMT1 interacts with and inhibits a protein complex termed TAK1, which is part of the NF-kB and TGFb signalling pathways. NF-kB and TGFb signalling are critically involved in transmitting stimuli within a cell, leading to alterations in the expression of target genes, and have known roles in brain function. As patients with KS have less functional EHMT1, we suggest that some of the clinical features of this disease could arise from overactivation of NF-kB and TGFb signalling. In this project, we aim to investigate how EHMT1 binds to and inhibits the TAK1 complex in order to downregulate NF-kB and TGFb signalling. We will utilize brain cells derived from stem cells of patients with KS as our model. We also propose to assess the cellular phenotypes of these brain cells to determine whether these human-derived cells show changes similar to what has been reported for animal models of KS. Finally, we will assess whether known drugs that inhibit NF-kB and TGFb can reverse any cellular phenotypes found. This work will reveal a novel molecular mechanism underlying KS and propose a new layer of regulation by EHMT1 on the TAK1 complex.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
497067
Name
Macintosh Julia E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
A new role for EHMT1 in repressing NF-kB and TGFb signaling in Kleefstra Syndrome
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Histone Methyltransferases; Induced Pluripotent Stem Cells; Kleefstra Syndrome; Neurodevelopmental Disorders; Neurogenetics; Rare Diseases
Abstract
Kleefstra syndrome (KS) is a neurodevelopmental disorder characterized by intellectual disability, low muscle tone, impaired immune responses, and craniofacial deformities. Genetic work has revealed the cause of KS to be the loss of one copy of the EHMT1 gene, though how decreases in EHMT1 expression cause disease is unclear. Recently, our lab has shown that EHMT1 interacts with and inhibits a protein complex termed TAK1, which is part of the NF-kB and TGFb signalling pathways. NF-kB and TGFb signalling are critically involved in transmitting stimuli within a cell, leading to alterations in the expression of target genes, and have known roles in brain function. As patients with KS have less functional EHMT1, we suggest that some of the clinical features of this disease could arise from overactivation of NF-kB and TGFb signalling. In this project, we aim to investigate how EHMT1 binds to and inhibits the TAK1 complex in order to downregulate NF-kB and TGFb signalling. We will utilize brain cells derived from stem cells of patients with KS as our model. We also propose to assess the cellular phenotypes of these brain cells to determine whether these human-derived cells show changes similar to what has been reported for animal models of KS. Finally, we will assess whether known drugs that inhibit NF-kB and TGFb can reverse any cellular phenotypes found. This work will reveal a novel molecular mechanism underlying KS and propose a new layer of regulation by EHMT1 on the TAK1 complex.
Competitiondate
202311
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Macintosh, Julia E
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~